Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/33570
Full metadata record
DC FieldValueLanguage
dc.contributor.authorEl-Habashy, Dina M-
dc.contributor.authorWahid, Kareem A.-
dc.contributor.authorHe, Renjie-
dc.contributor.authorMcDonald, Brigid-
dc.contributor.authorRigert, Jillian-
dc.contributor.authorNg, Sweet Ping-
dc.date2023-
dc.date.accessioned2023-08-23T07:20:05Z-
dc.date.available2023-08-23T07:20:05Z-
dc.date.issued2023-09-
dc.identifier.citationClinical and Translational Radiation Oncology 2023-09; 42en_US
dc.identifier.issn2405-6308-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/33570-
dc.description.abstractWe aim to characterize the serial quantitative apparent diffusion coefficient (ADC) changes of the target disease volume using diffusion-weighted imaging (DWI) acquired weekly during radiation therapy (RT) on a 1.5 T MR-Linac and correlate these changes with tumor response and oncologic outcomes for head and neck squamous cell carcinoma (HNSCC) patients as part of a programmatic R-IDEAL biomarker characterization effort. Thirty patients with HNSCC who received curative-intent RT at MD Anderson Cancer Center, were included. Baseline and weekly MRI were obtained, and various ADC parameters were extracted from the regions of interest (ROIs). Baseline and weekly ADC parameters were correlated with response during and after RT, and the recurrence using the Mann-Whitney U test. The Wilcoxon signed-rank test was used to compare the weekly ADC versus baseline values. Weekly volumetric changes (Δvolume) for each ROI were correlated with ΔADC using Spearman's Rho test. Recursive partitioning analysis (RPA) identified the optimal ΔADC threshold associated with different oncologic outcomes. There was a significant rise in all ADC parameters at different time points of RT compared to baseline for both gross primary disease (GTV-P) and gross nodal disease volumes (GTV-N). The increased ADC values for GTV-P were statistically significant only for primary tumors achieving complete remission (CR) during RT. RPA identified GTV-P ΔADC 5th percentile > 13% at the mid-RT as the most significant parameter associated with primary tumors' CR during RT (p < 0.001). There was a significant decrease in residual volume of both GTV-P & GTV-N throughout the course of RT. A significant negative correlation between mean ΔADC and Δvolume for GTV-P at the 3rd and 4th week of RT was detected (r = -0.39, p = 0.044 & r = -0.45, p = 0.019, respectively). Assessment of ADC kinetics at regular intervals throughout RT seems to be correlated with RT response. Further studies with larger cohorts and multi-institutional data are needed for validation of ΔADC as a model for prediction of response to RT.en_US
dc.language.isoeng-
dc.subjectADCen_US
dc.subjectDWIen_US
dc.subjectDiffusionen_US
dc.subjectHead and neck canceren_US
dc.subjectMR-Linacen_US
dc.subjectOncologic outcomesen_US
dc.titleLongitudinal diffusion and volumetric kinetics of head and neck cancer magnetic resonance on a 1.5 T MR-linear accelerator hybrid system: A prospective R-IDEAL stage 2a imaging biomarker characterization/pre-qualification study.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleClinical and Translational Radiation Oncologyen_US
dc.identifier.affiliationRadiation Oncologyen_US
dc.identifier.affiliationDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USAen_US
dc.identifier.affiliationDepartment of Clinical Oncology and Nuclear Medicine, Menoufia University, Shebin Elkom, Egypten_US
dc.identifier.affiliationDepartment of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USAen_US
dc.identifier.affiliationDepartment of Radiology, Radiation Oncology and Nuclear Medicine, Université de Montréal, Canadaen_US
dc.identifier.affiliationUniversity of Houston College of Pharmacy, Houston, TX, USAen_US
dc.identifier.affiliationDepartment of Radiation Therapy, University Medical Center Utrecht, Utrecht, The Netherlandsen_US
dc.identifier.affiliationDepartment of Head and Neck Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USAen_US
dc.identifier.affiliationDepartment of Molecular and Cellular Oncology, Division of Basic Science Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USAen_US
dc.identifier.affiliationPhilips Healthcare MR Oncology, Cleveland, OH, USAen_US
dc.identifier.affiliationElekta AB, Stockholm, Swedenen_US
dc.identifier.affiliationDepartment of Radiation Oncology, Baylor College of Medicine, Houston, TX, USAen_US
dc.identifier.doi10.1016/j.ctro.2023.100666en_US
dc.type.contentTexten_US
dc.identifier.pubmedid37583808-
dc.description.volume42-
dc.description.startpage100666-
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
crisitem.author.deptRadiation Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

66
checked on Dec 23, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.